Published in Front Cell Infect Microbiol on December 27, 2016
Host defense antimicrobial peptides as antibiotics: design and application strategies. Curr Opin Chem Biol (2017) 0.76
New Potent Membrane-Targeting Antibacterial Peptides from Viral Capsid Proteins. Front Microbiol (2017) 0.75
D-BMAP18 Antimicrobial Peptide Is Active In vitro, Resists to Pulmonary Proteases but Loses Its Activity in a Murine Model of Pseudomonas aeruginosa Lung Infection. Front Chem (2017) 0.75
Transcriptional Responses of Candida albicans to Antimicrobial Peptide MAF-1A. Front Microbiol (2017) 0.75
Antimicrobial peptides of multicellular organisms. Nature (2002) 23.50
Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol (2005) 13.69
Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol (2006) 10.15
Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med (2002) 9.01
Peptide antibiotics and their role in innate immunity. Annu Rev Immunol (1995) 6.81
Peptide antibiotics. Lancet (1997) 6.76
Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature (2001) 6.71
Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis (2005) 6.60
Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev (2003) 6.57
Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol (2004) 6.35
Peptide antimicrobial agents. Clin Microbiol Rev (2006) 6.04
Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell (1997) 5.99
Peptide antibiotics. Antimicrob Agents Chemother (1999) 5.76
Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta (1999) 4.71
The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat Rev Microbiol (2006) 4.29
Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov (2011) 4.16
The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol (2000) 4.10
Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest (1998) 3.51
AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol (2009) 3.40
Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol (2001) 3.39
Antimicrobial peptides: premises and promises. Int J Antimicrob Agents (2004) 3.39
Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care (2006) 3.35
Polymyxins revisited. Clin Microbiol Rev (2008) 3.16
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother (2007) 3.15
Synthetic therapeutic peptides: science and market. Drug Discov Today (2009) 2.95
Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol (2006) 2.95
Mesoporous materials for drug delivery. Angew Chem Int Ed Engl (2007) 2.93
Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem (1996) 2.78
The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol (2002) 2.57
The relationship between peptide structure and antibacterial activity. Peptides (2003) 2.51
Epithelial antimicrobial peptides in host defense against infection. Respir Res (2000) 2.40
The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol (2011) 2.35
Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol (2006) 2.32
Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature (2005) 2.23
Complicated skin and soft tissue infection. J Antimicrob Chemother (2010) 2.12
Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2000) 1.99
Multifunctional cationic host defence peptides and their clinical applications. Cell Mol Life Sci (2011) 1.99
Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials. Endocr Pract (2009) 1.93
Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol (2012) 1.86
Vitamin D induces the antimicrobial protein hCAP18 in human skin. J Invest Dermatol (2005) 1.82
Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem (2010) 1.79
The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol (2004) 1.78
Antimicrobial peptides stage a comeback. Nat Biotechnol (2013) 1.73
The human beta-defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. J Immunol (2005) 1.73
Control of cell selectivity of antimicrobial peptides. Biochim Biophys Acta (2008) 1.66
The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides. FASEB J (2006) 1.66
Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J Immunol (2005) 1.66
Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol Life Sci (2005) 1.59
Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am J Physiol Lung Cell Mol Physiol (2005) 1.57
Antimicrobial peptides: new candidates in the fight against bacterial infections. Biopolymers (2005) 1.50
Discovering and improving novel peptide therapeutics. Curr Opin Pharmacol (2008) 1.46
Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov (2003) 1.46
Antimicrobial peptides: key components of the innate immune system. Crit Rev Biotechnol (2011) 1.44
Advances in antimicrobial peptide immunobiology. Biopolymers (2006) 1.44
Methods and protocols of modern solid phase Peptide synthesis. Mol Biotechnol (2006) 1.42
Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis (2016) 1.37
Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. Cell Immunol (2002) 1.32
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis (2008) 1.30
Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37. Antimicrob Agents Chemother (2005) 1.28
To protect peptide pharmaceuticals against peptidases. J Pharmacol Toxicol Methods (2010) 1.27
Natural antimicrobial peptides from bacteria: characteristics and potential applications to fight against antibiotic resistance. J Appl Microbiol (2012) 1.27
Mechanism and fitness costs of PR-39 resistance in Salmonella enterica serovar Typhimurium LT2. Antimicrob Agents Chemother (2008) 1.16
Lubricin surface modification improves tendon gliding after tendon repair in a canine model in vitro. J Orthop Res (2009) 1.16
Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development. Future Microbiol (2011) 1.16
Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells. Pediatr Res (1996) 1.09
Structural determinants of host defense peptides for antimicrobial activity and target cell selectivity. Biochimie (2010) 1.07
Engineered endolysin-based "Artilysins" to combat multidrug-resistant gram-negative pathogens. MBio (2014) 1.06
Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int J Cancer (1999) 1.05
Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2014) 1.02
Effect of divalent cation removal on the structure of gram-negative bacterial outer membrane models. Langmuir (2014) 1.02
Highly selective end-tagged antimicrobial peptides derived from PRELP. PLoS One (2011) 1.02
Pexiganan acetate. Drugs (1998) 0.99
Cationic antimicrobial peptides: towards clinical applications. Expert Opin Investig Drugs (2000) 0.96
Mechanisms and fitness costs of resistance to antimicrobial peptides LL-37, CNY100HL and wheat germ histones. PLoS One (2013) 0.96
Human lactoferricin is partially folded in aqueous solution and is better stabilized in a membrane mimetic solvent. Antimicrob Agents Chemother (2005) 0.95
Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria. Future Microbiol (2015) 0.95
Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). BMC Med (2009) 0.94
Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis. Int J Antimicrob Agents (2012) 0.92
Improved methods for classification, prediction, and design of antimicrobial peptides. Methods Mol Biol (2015) 0.89
Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen (2014) 0.86
Effects of an LL-37-derived antimicrobial peptide in an animal model of biofilm Pseudomonas sinusitis. Am J Rhinol Allergy (2009) 0.86
Effective control of Salmonella infections by employing combinations of recombinant antimicrobial human β-defensins hBD-1 and hBD-2. Antimicrob Agents Chemother (2014) 0.84
LL-37 regulates the overexpression of vascular endothelial growth factor (VEGF) and c-IAP-2 in human keratinocytes. Int J Dermatol (2008) 0.84
Antimicrobial peptide hLF1-11 directs granulocyte-macrophage colony-stimulating factor-driven monocyte differentiation toward macrophages with enhanced recognition and clearance of pathogens. Antimicrob Agents Chemother (2009) 0.83
F2L, a peptide derived from heme-binding protein, inhibits LL-37-induced cell proliferation and tube formation in human umbilical vein endothelial cells. FEBS Lett (2007) 0.83
The novel antimicrobial peptide PXL150 in the local treatment of skin and soft tissue infections. Appl Microbiol Biotechnol (2012) 0.82
Antimicrobial peptides: their role as infection-selective tracers for molecular imaging. Biomed Res Int (2014) 0.81
Anti-infectious and anti-inflammatory effects of peptide fragments sequentially derived from the antimicrobial peptide centrocin 1 isolated from the green sea urchin, Strongylocentrotus droebachiensis. AMB Express (2012) 0.81
Incorporation of antimicrobial compounds in mesoporous silica film monolith. Biomaterials (2009) 0.81
Mechanisms and consequences of bacterial resistance to antimicrobial peptides. Drug Resist Updat (2016) 0.81
The effect of lubricin on the gliding resistance of mouse intrasynovial tendon. PLoS One (2013) 0.80
A novel polypeptide derived from human lactoferrin in sodium hyaluronate prevents postsurgical adhesion formation in the rat. Ann Surg (2009) 0.80
Membrane interactions of mesoporous silica nanoparticles as carriers of antimicrobial peptides. J Colloid Interface Sci (2016) 0.79
LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive Staphylococcus aureus. Antimicrob Agents Chemother (2014) 0.79
PXL01 in sodium hyaluronate for improvement of hand recovery after flexor tendon repair surgery: randomized controlled trial. PLoS One (2014) 0.79
Understanding the adsorption of salmon calcitonin, antimicrobial peptide AP114 and polymyxin B onto lipid nanocapsules. Int J Pharm (2016) 0.79
Overcoming barriers in Pseudomonas aeruginosa lung infections: Engineered nanoparticles for local delivery of a cationic antimicrobial peptide. Colloids Surf B Biointerfaces (2015) 0.78
Solid phase protein chemical synthesis. Top Curr Chem (2015) 0.78
Efficacy of Artilysin Art-175 against Resistant and Persistent Acinetobacter baumannii. Antimicrob Agents Chemother (2016) 0.78
Antibacterial action of lipid nanocapsules containing fatty acids or monoglycerides as co-surfactants. Eur J Pharm Biopharm (2016) 0.78